About immutep ltd - IMMP
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
IMMP At a Glance
Immutep Ltd.
Australia Square
Sydney, New South Wales (NSW) 2000
| Phone | 61-2-8315-7003 | Revenue | 9.86M | |
| Industry | Biotechnology | Net Income | -53,738,591.14 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 06 / 2027 | |||
| View SEC Filings |
IMMP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.22 |
| Price to Book Ratio | 1.441 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.26 |
| Enterprise Value to Sales | 1.456 |
| Total Debt to Enterprise Value | 0.051 |
IMMP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 1.48 |
| Total Asset Turnover | 0.123 |
IMMP Liquidity
| Current Ratio | 5.694 |
| Quick Ratio | 5.694 |
| Cash Ratio | 4.864 |
IMMP Profitability
| Gross Margin | 83.011 |
| Operating Margin | -576.212 |
| Pretax Margin | -544.789 |
| Net Margin | -544.789 |
| Return on Assets | -66.936 |
| Return on Equity | -78.587 |
| Return on Total Capital | -123.948 |
| Return on Invested Capital | -78.169 |
IMMP Capital Structure
| Total Debt to Total Equity | 1.702 |
| Total Debt to Total Capital | 1.674 |
| Total Debt to Total Assets | 1.258 |
| Long-Term Debt to Equity | 1.231 |
| Long-Term Debt to Total Capital | 1.21 |